NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.19 USD | +11.38% |
|
+16.03% | -4.96% |
| 05-02 | NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue | MT |
| 05-02 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,340 | 17,615 | 7,795 | 7,698 | 1,595 | 1,527 | - | - |
| Enterprise Value (EV) 1 | 8,312 | 17,810 | 8,148 | 8,148 | 1,923 | 1,860 | 1,761 | 1,700 |
| P/E ratio | -1,204 x | 865 x | -134 x | -83.4 x | -7.66 x | -9.21 x | -7.97 x | -8.63 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.7 x | 35.6 x | 14.6 x | 14.3 x | 3.13 x | 2.75 x | 2.61 x | 2.31 x |
| EV / Revenue | 23.7 x | 36 x | 15.2 x | 15.1 x | 3.78 x | 3.35 x | 3.01 x | 2.57 x |
| EV / EBITDA | 1,102 x | 450 x | -239 x | -103 x | -8.67 x | -9.73 x | -8.75 x | -8.33 x |
| EV / FCF | 515 x | 212 x | 139 x | 864 x | -19.2 x | -13.6 x | -14 x | -10.3 x |
| FCF Yield | 0.19% | 0.47% | 0.72% | 0.12% | -5.22% | -7.33% | -7.12% | -9.71% |
| Price to Book | 38.5 x | 37.2 x | 19 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 98,969 | 101,797 | 103,819 | 104,950 | 106,861 | 107,606 | - | - |
| Reference price 2 | 84.27 | 173.0 | 75.08 | 73.35 | 14.93 | 14.19 | 14.19 | 14.19 |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 351.3 | 494.4 | 535 | 537.8 | 509.3 | 555.6 | 584.2 | 661 |
| EBITDA 1 | 7.546 | 39.55 | -34.08 | -78.9 | -221.9 | -191.2 | -201.3 | -204.1 |
| EBIT 1 | -0.914 | 30.4 | -44.33 | -89.52 | -232.9 | -215.1 | -220.5 | -191.9 |
| Operating Margin | -0.26% | 6.15% | -8.29% | -16.64% | -45.72% | -38.72% | -37.75% | -29.03% |
| Earnings before Tax (EBT) 1 | -8.824 | 18.1 | -52.08 | -81.85 | -191.7 | -170.1 | -189 | -162.5 |
| Net income 1 | -7.23 | 19.81 | -58.35 | -92.53 | -207 | -179.8 | -198 | -170.6 |
| Net margin | -2.06% | 4.01% | -10.91% | -17.2% | -40.65% | -32.36% | -33.89% | -25.81% |
| EPS 2 | -0.0700 | 0.2000 | -0.5600 | -0.8800 | -1.950 | -1.540 | -1.781 | -1.644 |
| Free Cash Flow 1 | 16.14 | 84.18 | 58.59 | 9.43 | -100.4 | -136.4 | -125.5 | -165 |
| FCF margin | 4.59% | 17.03% | 10.95% | 1.75% | -19.72% | -24.55% | -21.48% | -24.96% |
| FCF Conversion (EBITDA) | 213.82% | 212.84% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 424.98% | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 133.2 | 137.5 | 140.9 | 131 | 128.4 | 122.2 | 126.1 | 127.3 | 133.8 | 138.5 | 136.7 | 139 | 141.4 | 143.8 | 143.6 |
| EBITDA 1 | -20.73 | 1.804 | -18.47 | -21.95 | -40.28 | -57.53 | -59.94 | -55.44 | -48.99 | -38.7 | -53.39 | -52.4 | -48.84 | -42.87 | -53.94 |
| EBIT 1 | -23.4 | -0.806 | -21.13 | -24.61 | -42.98 | -60.25 | -62.66 | -58.24 | -51.72 | -41.52 | -54.39 | -55.58 | -56.15 | -45.88 | -57.01 |
| Operating Margin | -17.56% | -0.59% | -15% | -18.79% | -33.46% | -49.31% | -49.71% | -45.75% | -38.66% | -29.98% | -39.79% | -39.98% | -39.72% | -31.91% | -39.7% |
| Earnings before Tax (EBT) 1 | -25.57 | -2.515 | -23.36 | -23.42 | -32.56 | -51.08 | -53.9 | -48.22 | -38.53 | -31.64 | -47.38 | -47.44 | -44.93 | -39.51 | -50.63 |
| Net income 1 | -26.46 | -4.647 | -24.01 | -26.58 | -37.3 | -53.06 | -57.42 | -49.48 | -47.08 | -38.76 | -44.74 | -46.47 | -47.27 | -39.51 | -50.63 |
| Net margin | -19.86% | -3.38% | -17.04% | -20.29% | -29.05% | -43.43% | -45.55% | -38.87% | -35.19% | -27.98% | -32.73% | -33.43% | -33.44% | -27.48% | -35.26% |
| EPS 2 | -0.2500 | -0.0400 | -0.2300 | -0.2500 | -0.3600 | -0.5000 | -0.5400 | -0.4600 | -0.4500 | -0.3600 | -0.4019 | -0.4144 | -0.4298 | -0.3650 | -0.4200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-02-24 | 22-04-28 | 22-07-28 | 22-10-27 | 23-02-23 | 23-05-04 | 23-07-27 | 23-10-26 | 24-02-22 | 24-05-02 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 195 | 353 | 450 | 328 | 333 | 234 | 173 |
| Net Cash position 1 | 27.9 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 4.936 x | -10.37 x | -5.706 x | -1.478 x | -1.741 x | -1.163 x | -0.8486 x |
| Free Cash Flow 1 | 16.1 | 84.2 | 58.6 | 9.43 | -100 | -136 | -125 | -165 |
| ROE (net income / shareholders' equity) | -4.38% | 5.71% | -13.2% | -21.7% | -51.5% | -68.4% | -153% | -420% |
| ROA (Net income/ Total Assets) | -1.77% | 2.59% | -5.33% | -7.94% | -17.7% | -19% | -25.5% | -19.3% |
| Assets 1 | 409.6 | 765.7 | 1,096 | 1,166 | 1,169 | 944.2 | 776.1 | 882.9 |
| Book Value Per Share | 2.190 | 4.660 | 3.950 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 10.5 | 15 | 24.2 | 21.4 | 27.1 | 25 | 29.5 | 42 |
| Capex / Sales | 2.98% | 3.03% | 4.52% | 3.97% | 5.32% | 4.5% | 5.05% | 6.35% |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
14.19
USD
Average target price
25.57
USD
Spread / Average Target
+80.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.96% | 1.53B | |
| +73.17% | 12.38B | |
| -18.08% | 7.99B | |
| +16.24% | 7.21B | |
| +3.43% | 5.79B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.74% | 4.17B | |
| -35.34% | 2.44B | |
| +2.10% | 2.03B |
- Stock Market
- Equities
- NVCR Stock
- Financials NovoCure Limited
